LSL Pharma Group (TSXV:LSL) Beta: -0.5637 (As of Jun. 25, 2026)


TSXV:LSL LSL Pharma Group Inc TSXV:LSL
49 GF Score
Price C$0.32
GF Value C$0.72
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is LSL Pharma Group Beta?

LSL Pharma Group TSXV:LSL 49 Beta is -0.5637 as of Jun. 25, 2026. GuruFocus rates TSXV:LSL with a GF Score™ of 49/100 and a GF Value™ of C$0.72 (Possible Value Trap). The stock has 6 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), LSL Pharma Group's Beta is -0.5637.

LSL Pharma Group  (TSXV:LSL) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

LSL Pharma Group Beta Related Terms

LSL Pharma Group Beta Historical Data

* Premium members only.

The historical data trend for LSL Pharma Group's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LSL Pharma Group Beta Chart

LSL Pharma Group Annual Data
Trend Sep20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

LSL Pharma Group Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.41

TSXV:LSL vs ZTS: Beta Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, LSL Pharma Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LSL Pharma Group Beta vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, LSL Pharma Group's Beta distribution charts can be found below:

* The bar in red indicates where LSL Pharma Group's Beta falls into.


TSXV:LSL
49GF Score
LSL Pharma Group Inc TSXV:LSL
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LSL Pharma Group Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -0.5637 mean?
LSL Pharma Group (TSXV:LSL) has a Beta of -0.5637 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for LSL Pharma Group and its competitors.
Is LSL Pharma Group's Beta too high?
LSL Pharma Group's current Beta is -0.5637. Overall, LSL Pharma Group has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does LSL Pharma Group's Beta compare to ZTS?
LSL Pharma Group's Beta of -0.5637 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Drug Manufacturers company?
A good Beta depends on the Drug Manufacturers industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for LSL Pharma Group and its competitors. LSL Pharma Group's current Beta is -0.5637. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LSL Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, LSL Pharma Group (TSXV:LSL) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.72, compared to a current price of C$0.32 — trading 55.6% below its estimated fair value. The current Beta is -0.5637. LSL Pharma Group's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For LSL Pharma Group (TSXV:LSL), the current Beta is -0.5637 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LSL Pharma Group (TSXV:LSL) Overvalued in 2026?

Based on GuruFocus' analysis, LSL Pharma Group stock appears to be undervalued. The current stock price of C$0.32 is trading 55.6% below its estimated GF Value™ of C$0.72. GuruFocus considers LSL Pharma Group to be Possible Value Trap.

Key valuation signals for TSXV:LSL:

  • Beta: -0.5637
  • GF Value™: C$0.72 vs. price of C$0.32 (55.6% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the TSXV:LSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LSL Pharma Group Business Description

Address 540, rue d\'Avaugour, Bureau 1800, Boucherville, QC, CAN, J4B 0G6
LSL Pharma Group Inc develops, manufactures and commercializes sterile pharmaceutical products, cosmetic products and natural health products. It operates in three segments CMO activities include four operating entities LSL Laboratory, Dermolab, Du-Var, and VSI; Integrated Eye-care pharmaceutical company which includes sterile Eye-care manufacturing operation; and Private Label Business includes Juno OTC which commercializes pharmaceutical products with a focus on private label, over the counter (OTC) products. It derives majority of revenue from CMO activities segment.
49GF Score

Get the complete analysis for TSXV:LSL

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.32
Price
C$0.72
GF Value